Insulinoma
Conditions
Interventions
A total of 9 patients will receive an injection of Exendin-800CW 24 hours
before surgery. Directly after surgery the pancreatic tissue will be examined
on the back-table and by image-guided patholog
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age equal to or older than 18 years;- Patients who are scheduled to undergo a pancreatectomy due to an insulinoma, another type of neuro-endocrine tumour or because of a suspected carcinoma.;- WHO performance score 0-2;- Signed informed consent
Exclusion criteria
Exclusion criteria: - Breast feeding;- Pregnancy or the wish to become pregnant within 6 months;- Calculated creatinine clearance below 40ml/min;- Evidence of other malignancy in conventional imaging (suspicious liver, bone and lung lesions);- No informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Back-table imaging of the surgical specimen directly after excision to identify fluorescence signals of Exendin-800CW - Correlation of fluorescence signals with histology. - Calculating target to background ratios in fluorescence imaging obtained directly after the surgical procedure and fluorescence images obtained during ex vivo analyses in bread loaf slices and in histological slices (odyssey scanner, fluorescence microscopy). - Adverse events (AE), serious adverse events (SAE), and suspected unsuspected serious adverse reactions (SUSARs). | — |
Secondary
| Measure | Time frame |
|---|---|
| - | — |
Countries
Netherlands
Outcome results
None listed